Leading Growth Driver in the Trastuzumab Biosimilars Market in 2025: Rising Breast And Gastric Cancer Prevalence Drives Trastuzumab Biosimilars Market. Driver's Influence

What Are the Market Size and Growth Forecast for the Trastuzumab Biosimilars Market?
The market for trastuzumab biosimilars has witnessed significant expansion in the past few years. The market is projected to increase from $4.27 billion in 2024 to $5.43 billion in 2025, with a compound annual growth rate (CAGR) of 27.1%. The historical growth patterns can be attributed to the expansion and globalization of the market, expiry of patents and subsequent market entries, accelerated development of biosimilars, validation of clinical efficacy, and competitive pricing strategies.

The market size for trastuzumab biosimilars is predicted to experience a remarkable surge in the upcoming years, expanding to a size of $14.69 billion by 2029 with a CAGR of 28.3%. The surge during the forecast period is primarily attributed to factors such as increasing market competition, development of biosimilar pipelines, regulatory standardizations and approvals, global market penetration, and the changing adoption and prescription behaviours of physicians. The period is also expected to witness major shifts in the form of greater access, strategic market segmentations, educational promotions, patient inclinations towards biosimilars, and increased acceptance by physicians.

What Is Contributing to the Growth of the Trastuzumab Biosimilars Market?
The trastuzumab biosimilars market is experiencing growth due to an increase in cases of breast and gastric cancer. Trastuzumab biosimilar, used to treat human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer, is seeing increased demand. For example, the American Cancer Society, a US-based non-profit organization committed to cancer eradication, predicted that in September 2023, approximately 297,790 fresh occurrences of invasive breast cancer will be identified in women, and around 43,700 women will succumb to the disease that year. As per Cancer India, breast cancer is the predominant form of cancer among females in India, constituting 14% of all female cancer cases. Consequently, the surge in breast and gastric cancer cases enhances the demand for cost-effective trastuzumab biosimilar solutions, thereby propelling the trastuzumab biosimilars market forward.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

Which Key Market Leaders Are Driving Trastuzumab Biosimilars Industry Growth?
Major companies operating in the trastuzumab biosimilars market include Pfizer Inc., Merck & Co., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Torrent Pharmaceuticals Limited

What Are the Emerging Trends in the Trastuzumab Biosimilars Industry?
Key market participants are persistently concentrating on introducing new products in previously unexplored regions, thereby influencing the trastuzumab biosimilars market landscape. Companies in this market are undertaking multiple strategic maneuvers, like developing new products, forming alliances, and expanding geographically and product-wise, to fortify their competitive standing and to better cater to their consumers. For example, in April 2024, US-based Accord BioPharma Inc., unveiled that the U.S. Food and Drug Administration (FDA) had accorded approval for their biosimilar to Herceptin (trastuzumab), HERCESSI (trastuzumab-strf), intended to treat various types of HER2-Overexpressing Cancer. Recommended for the adjunct therapy for HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma, HERCESSI is particularly effective against typically aggressive HER2-positive cancers due to its targeted therapy. By binding to the HER2 receptor, it inhibits its functionality and consequently decelerates the multiplication of cancer cells.

What Are the Main Segments in the Trastuzumab Biosimilars Market?
The trastuzumab biosimilars market covered in this report is segmented -

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Geographic Area Leads the Trastuzumab Biosimilars Market?
The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Is Covered In The Trastuzumab Biosimilars Global Market Report?

- Market Size Analysis: Analyze the Trastuzumab Biosimilars Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Trastuzumab Biosimilars Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Trastuzumab Biosimilars Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Trastuzumab Biosimilars Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3400

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.